The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.
Be diagnosed as DLBCL
Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment
Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail
Cohort 3: relapse or refractory to previous treatment
Participant who currently participates in or with plan to participate in any interventional clinical trial
Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
Participants who will be treated with polatuzumab (known as being recommended and having the intention to be treated with polatuzumab at the time of signing informed consent) or have initiated polatuzumab treatment within three months prior to enrollment and after the indication approval will be observed in this study.
Cohort
Prospective
Polatuzumab Vedotin
DrugPolatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
Cohorts 1 and 2: Progression Free Survival at 24 months (PFS24) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma
Cohort 3: PFS Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma
Cohort 3: PFS24 Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma
Cohorts 1, 2 and 3: Time to Next Treatment (TTNT)
Cohorts 1, 2 and 3: Complete Response Rate (CRR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma
Cohorts 1, 2 and 3: Overall Response Rate (ORR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma
Click on the lead sponsor to view all of their trials.
